195 related articles for article (PubMed ID: 38387463)
1. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
4. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
5. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
6. Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53.
Calheiros J; Corbo V; Saraiva L
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188914. PubMed ID: 37201730
[TBL] [Abstract][Full Text] [Related]
7. DNA excision repair and DNA damage-induced apoptosis are linked to Poly(ADP-ribosyl)ation but have different requirements for p53.
Beneke R; Geisen C; Zevnik B; Bauch T; Müller WU; Küpper JH; Möröy T
Mol Cell Biol; 2000 Sep; 20(18):6695-703. PubMed ID: 10958667
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
9. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase (PARP-1) and p53 independently function in regulating double-strand break repair in primate cells.
Süsse S; Scholz CJ; Bürkle A; Wiesmüller L
Nucleic Acids Res; 2004; 32(2):669-80. PubMed ID: 14757832
[TBL] [Abstract][Full Text] [Related]
11. Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1.
Tao L; Xia X; Kong S; Wang T; Fan F; Wang W
Pharmacol Res; 2024 Mar; 201():107091. PubMed ID: 38316371
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
14. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
16. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.
Zonneville J; Wang M; Alruwaili MM; Smith B; Melnick M; Eng KH; Melendy T; Park BH; Iyer R; Fountzilas C; Bakin AV
Commun Biol; 2021 Jul; 4(1):862. PubMed ID: 34253820
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Tentori L; Portarena I; Bonmassar E; Graziani G
Cell Death Differ; 2001 May; 8(5):457-69. PubMed ID: 11423906
[TBL] [Abstract][Full Text] [Related]
18. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.
Jarrar A; Lotti F; DeVecchio J; Ferrandon S; Gantt G; Mace A; Karagkounis G; Orloff M; Venere M; Hitomi M; Lathia J; Rich JN; Kalady MF
Stem Cells; 2019 Jan; 37(1):42-53. PubMed ID: 30353615
[TBL] [Abstract][Full Text] [Related]
20. mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance.
Bu C; Zhao L; Wang L; Yu Z; Zhou J
Oncol Res; 2023; 31(4):495-503. PubMed ID: 37415733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
